couter

FENCFennec Pharmaceuticals Inc.

Health CareBiotechnology

The Read

FENC has historically shown a median absolute move of about 12%.
Oct 20, 2026 — CMS Reimbursement Policy Rev
Chart by TradingView

The schedule

  • Tue20Oct

    Potential regulatory update on CMS reimbursement policies, which could impact revenue and operations.

  • Thu12Nov

    Earnings report and guidance for Q3 2026, with potential impact from regulatory updates and revenue performance.

  • Sun14Feb

    Earnings report and guidance for Q4 2026, with potential impact from regulatory updates and revenue performance.

  • Thu13May

    Earnings report and guidance for Q1 2027, with potential impact from regulatory updates and revenue performance.

  • Thu12Aug

Past

  • Thu13Aug

    Actual outcome: Bull · $11.72 at outcome

    Fennec Pharmaceuticals reported strong Q2 2026 results, with net product sales surging 78% year-over-year to $17.1 million driven by rising demand for its PEDMARK therapy. The company also posted EPS of $0.05, beating analyst estimates of $0.01 per share. This robust top- and bottom-line performance validated the company's growth trajectory, propelling the stock past the $11.20 bull target.

    Fennec's recent pivot to positive EPS ($0.01 on $15.1M revenue in Q1) sets a high bar for Q2. Revenue growth of 72.6% YoY will be tested against EU PEDMARQSI royalty updates and U.S. sales momentum.

  • Wed8Jul

    Actual outcome: Bull · $10.60 at outcome

    FENC experienced a muted initial reaction around its expected capital allocation and business development update, rising just 3.4% by the outcome date. With no major strategic announcements or fundamental drivers detailed in the available news beyond early options market speculation, the stock lacked the momentum to test the bull target and eventually drifted lower toward the bear floor by late July.

    FENC is expected to provide a strategic update following its debt payoff and first profitable quarter.

  • Fri27Mar

    Actual outcome: Bear · $6.17 at outcome

    Fennec Pharmaceuticals reported a Q4 loss of $0.11 per share and missed revenue estimates, overshadowing its announcement of record full-year PEDMARK sales of $44.6 million. The wider-than-expected quarterly loss and revenue shortfall disappointed investors, driving the stock down through the bear floor immediately following the earnings release.

    Release of full-year 2025 results and critical forward guidance for PEDMARK commercialization under the current administration's healthcare cost-containment environment.